Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085 | Terminated Phase 1 FDA Drug

• 1 other identifier: ALXN2050-HV-109
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 2

Brief Summary

This study will investigate the impact of impaired hepatic function (IHF) on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with varying degrees of IHF.

Conditions

Impaired Hepatic Function; Healthy

Keywords

Pharmacokinetics; Safety; Factor D inhibitor; ALXN2050

Outcome Measures

Primary Outcomes (3)

• Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state

  Up to 72 hours postdose

• Maximum (Peak) Steady-state Plasma Concentration Of ALXN2050 (Cmax,ss)

  Up to 72 hours postdose

• Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)

  Up to 72 hours postdose

Secondary Outcomes (1)

• Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events

  Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)

Study Arms (1)

ALXN2050

EXPERIMENTAL

Cohort 1: Mild IHR Cohort 2: Moderate IHR Cohort 3: Severe IHR Cohort 4: Healthy Control Participants will receive ALXN2050

Drug: ALXN2050

Interventions

ALXN2050 DRUG

ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.

Also known as: ACH-0145228 (formerly)

ALXN2050

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Body weight must be at least 50.0 kilograms (kg) and body mass index (BMI) within the range of 18.0 - 40.0 kg/meter squared (inclusive) at the time of signing the informed consent.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Must agree to receive prophylactic antibiotics to mitigate the potential risk of meningococcal infection.
• Participants with Impaired Hepatic Function
• Aside from IHF, sufficiently healthy for study participation based upon medical history, physical examination, neurological examination, laboratory tests, vital signs, and electrocardiograms (ECGs).
• Score on the Child-Pugh scale at screening as follows:
• Mild: Class A (Child-Pugh score ≥5 and ≤6); or
• Moderate: Class B (Child-Pugh score ≥7 and ≤9); or
• Severe: Class C (Child-Pugh score ≥10 and ≤15).
• Diagnosis of chronic (\>6 months), stable (no acute episodes of illness within the previous 1 month due to deterioration in hepatic function) hepatic insufficiency.
• Must be on a stable medication regimen. Concomitant medications must be approved by Alexion unless presented in the list of common concurrent medications for participants with IHF.
• Cirrhosis, as evidenced by parenchymal liver disease by biopsy (histological diagnosis), imaging test, or other suitable imaging study, due to chronic hepatitis C virus (HCV) infection, chronic hepatitis B infection, cryptogenic, alcohol abuse, or non-alcoholic steatohepatitis.
• No evidence of hepatocellular carcinoma as documented by imaging within 6 months prior to the first dose of study intervention.
• Matched Healthy Control Participants with Normal Hepatic Function
• Must match the sex (similar ratio) and race (similar ratio of white and non-white) of participants with IHF; age must be within ± 10 years and BMI must be within ± 20% of participants with IHF at screening.

You may not qualify if:

• History or presence of seizures, head injury, head trauma, or any other brain disorder.
• History of procedures that could alter absorption or excretion of orally administered drugs.
• History of meningococcal infection or a first-degree relative with a history of meningococcal infection.
• Body temperature ≥38.0°Celcius at screening or check-in or history of febrile illness or other evidence of infection, systemic or otherwise, within 14 days prior to the first dose of study intervention.
• Classical pathway hemolysis results outside the reference ranges at screening, unless approved by Alexion.
• Significant blood loss or donation of blood within 3 months prior to the first dose of study intervention, donation of plasma within 30 days prior to the first dose of study intervention, receipt of blood products within 6 months prior to first dose of study intervention, or receipt of a vaccine within 30 days prior to the first dose of study intervention.
• Current enrollment or past participation within the last 30 days (or 5 half-lives, whichever is longer) prior to the first dose of study intervention in the current clinical study or any other clinical study involving an investigational study intervention or any other type of medical research.
• Pregnant or lactating.
• History or presence of drug or alcohol abuse within 6 months prior to the first dose of study intervention, current tobacco user, or positive results for alcohol and/or drug screen at screening or check-in.

Sponsors & Collaborators

• Alexion Pharmaceuticals, Inc.: lead

Study Sites (2)

Research Site

Hialeah, Florida, 33014, United States

Location

Research Site

Orlando, Florida, 32809, United States

Location

MeSH Terms

Interventions

rhoA GTP-Binding Protein

Intervention Hierarchy (Ancestors)

rho GTP-Binding Proteins; Monomeric GTP-Binding Proteins; GTP-Binding Proteins; GTP Phosphohydrolases; Acid Anhydride Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Carrier Proteins; Proteins; Amino Acids, Peptides, and Proteins; Intracellular Signaling Peptides and Proteins

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 5, 2020
• First Posted: February 28, 2022
• Study Start: April 7, 2022
• Primary Completion: August 12, 2024
• Study Completion: August 12, 2024
• Last Updated: March 19, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)